Single-center comparison of gel microcolumn and solid-phase methods for antibody screening by Schmidt, Anne et al.
IMMUNOHEMATOLOGY, Volume 29, Number 3, 2013 101
Single-center comparison of gel microcolumn 
and solid-phase methods for antibody 
screening
A.M. Schmidt, B.J. Bendix, E.K. Jacob, S.C. Bryant, and J.R. Stubbs
RepoRt
Our facility changed antibody screening methods from a 
gel microcolumn–based test (ID-Micro Typing System Gel 
Test; Ortho Clinical Diagnostics, Inc., Raritan, NJ) to an 
automated solid-phase test (Galileo/Capture-R Ready-Screen 
[I and II], Immucor, Inc., Norcross, GA). To determine whether 
detection rates for commonly encountered clinically significant 
red blood cell antibodies differed as a consequence of this 
change, preimplementation and postimplementation antibody 
identification records were retrospectively reviewed. A statistically 
significant difference in the percentage of positive screening tests 
during the gel microcolumn testing period (73,903 total screens, 
1.56% confirmed positive) versus the solid-phase screening period 
(80,242 total screens, 1.81% confirmed positive; p < 0.0002) 
was observed. The number of antibodies to K identified was 
significantly lower with solid phase than with gel (27% decrease; 
p = 0.004). It is unknown whether there is a statistical difference 
in delayed or hemolytic transfusion reaction rates as this was not 
evaluated. Immunohematology 2013;29:101–04.
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When a transfusion service or laboratory implements 
new red blood cell (RBC) antibody detection methods, it is 
likely that differences in the sensitivity and specificity of these 
methods will be observed. The choice of the system must 
take into account its limitations as well as its advantages over 
the system currently in use (ease of use, reproducibility, cost 
effectiveness, turnaround time, etc.). Ultimately, a system 
should be chosen that most effectively and efficiently meets the 
needs of the patients and workflow of the laboratory. This has 
been the case at our institution as outlined later.
Ours is a large academic tertiary-care facility with more than 
2000 beds and 96 operating rooms serving 350,000 patients 
per year in various surgical and medical specialties, including 
a large solid-organ and hematopoietic progenitor cell transplant 
center. A blood donor center and a busy transfusion service are 
supported by the laboratory, and each year during the period of 
this study, more than 45,000 RBC units were transfused and 
approximately 49,000 antibody screens were performed.
In 1993, the polyethylene glycol (PEG) tube method for 
RBC antibody screening was implemented as the primary 
method for most patients requiring such testing at our 
institution.1 An early automated version of solid-phase 
technology (IBG Systems, Shoreham-by-Sea, England, later 
purchased by Immucor, Inc., Norcross, GA) was used for 
screening of blood donors and next-day surgical patients. 
When the early solid-phase system could no longer be 
maintained, we explored the options that were available to 
meet the automation needs of a high test-volume blood bank. 
At that time, automation options were limited.
In 2004, an automated instrument (Tecan MEGAFlex ID, 
Ortho Clinical Diagnostics, Inc., Raritan, NJ) was purchased 
for ABO determination and antibody screens for blood donors 
and next-day surgical patients. We decided to use the gel 
method (ID-Micro Typing System, Ortho Clinical Diagnostics 
Inc.) for our antibody screening because it best fit our 
automation needs at the time. At the same time, the manual gel 
microcolumn method replaced the PEG method for antibody 
screening of all other patients. (Both gel microcolumn methods 
will subsequently be identified as gel).
In 2007, the gel test and its supporting automation were 
replaced with the fully automated solid-phase testing platform 
(Capture-R Ready-Screen [I and II] on Galileo, Immucor, Inc.). 
This instrument performed antibody screening and ABO 
testing on patients and blood donors, while PEG tube was used 
as our backup method. The switch was made to accommodate a 
more automated workflow in our high test-volume institution.
Throughout the process, limitations of each automated 
system were considered. Each piece of automation is restricted 
in some manner, whether it is sensitivity, specificity, ease of 
use, reproducibility, cost of instrumentation, reagent costs, 
turnaround time, etc.2–5 This study was undertaken to allow 
comparisons of two methods and automated systems during a 
multiyear period at a single institution.
Materials and Methods
A retrospective review of RBC serologic records from 
November 1, 2005, to December 31, 2008, was performed. 
102 IMMUNOHEMATOLOGY, Volume 29, Number 3, 2013
A.M. Schmidt et al.
For individual patients, data collection dated back to the 
first time a positive antibody screen result was documented 
using either a gel or a solid-phase method. Patients who had 
a positive antibody screen obtained via the PEG tube method 
and those who had an initial workup performed using an 
antibody identification panel were not included in the analysis. 
Blood donor data also were not included in this study. 
Subjects included in this analysis were not further selected 
by age or underlying diagnosis. Consent to undergo research 
investigation was verified for all study subjects, and the study 
was approved by the local institutional review board.
Data on antibody screen procedures performed using the 
gel methods (manual and automated) from November 2005 
to April 2007 were collected. The automated and manual gel 
methods were performed using the manufacturer’s procedures 
and a two-cell screening set (0.8% Selectogen, Ortho Clinical 
Diagnostics). Reactions were graded and recorded using 
standard criteria.6,7
Data on solid-phase antibody screening from June 2007 
to December 2008 were collected. Automated solid-phase 
testing was performed (Galileo, Capture-R Ready-Screen [I 
and II] Immucor, Inc.), which contains microtiter wells coated 
with screening cells. A two-cell screening technique was used. 
The manufacturer’s instructions for carrying out the assay and 
determining reaction grades were followed.8
The PEG tube method was used for antibody identification 
during both the gel and the solid-phase screening periods. 
Comparison of the identified antibodies was limited to 
common clinically significant specificities, to allow for 
statistical analysis. Antibodies identified singly as well as in 
conjunction with other specificities were included.
Poisson regression was used to assess the statistical 
difference in incidence (detection rate) of positive screens 
between the gel method and the Galileo method for overall 
positive screens, as well as for specific antibodies, with the 
dependent variable being the incidence of positive screens 
(overall, subsequently by antibody) and the independent 
variable being method of screening, with an offset being log-
total number of screens by each method. All analyses were 
performed using a statistics program (SAS version 9.1.3, SAS 
Institute Inc., Cary, NC). Overall significance was defined as 
a probability value less than 0.05, with significance of specific 
antibodies less than 0.0045 to allow for multiple comparisons.
Results
Of 73,903 antibody screens performed with the gel 
method, 1153 positive screens (1.56%) were confirmed by 
manual PEG method. Using the Galileo method, 80,242 
antibody screens were performed, and 1449 positive screens 
(1.81%) were confirmed by the manual PEG method. This 
difference was statistically significant (Poisson regression, 
p < 0.002). In Table 1, the specificities and total numbers 
of commonly encountered, clinically significant RBC 
alloantibodies identified with the two antibody screening 
methods are presented (anti-D was excluded from this study 
owing to the high incidence of passive antibody detected). 
A statistically significant decreased number of antibodies to 
K was identified with the switch from the gel method to the 
subsequent solid-phase method (190 vs. 150, 27% decrease 
in detection rate; p = 0.004). This is in contrast to the number 
of antibodies to Jka identified, which was higher with the 
Table 1. Results of each antibody specificity detected using gel and solid-phase methodology*
Antibody 
specificity
















rate Change (%) p value
E 138 87 225 0.003045 171 80 251 0.003128 3 0.77
c 17 25 42 0.000568 19 21 40 0.000498 –12 0.55
C 18 58 76 0.001028 19 54 73 0.000910 –12 0.45
e 4 7 11 0.000149 5 3 8 0.000100 –33 0.39
K 134 56 190 0.002571 117 33 150 0.001869 –27 0.004
Fya 44 17 61 0.000825 32 24 56 0.000698 –15 0.36
Fyb 0 1 1 0.000014 2 1 3 0.000037 176 0.38
S 10 7 17 0.000230 6 9 15 0.000187 –19 0.56
s 1 0 1 0.000014 3 1 4 0.000050 268 0.24
Jka 21 14 35 0.000474 37 24 61 0.000760 61 0.03
Jkb 3 5 8 0.000108 2 13 15 0.000187 73 0.21
*Detection rates (incidence) were calculated to account for the variability in the total number of screens performed in each period: gel method = 73,903 
screens, solid-phase method = 80,242 screens. For individual antibody comparisons, the statistical significance was defined as a probability value of ≤ 0.0045.
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solid-phase method but did not reach statistical significance 
(35 vs. 61, 61% increase in detection rate; p = 0.03). The relative 
numbers of antibodies to s, Fya, and Jkb detected with the 
solid-phase method compared with the gel method were 268 
percent, 176 percent, and 73 percent higher, respectively. These 
differences, however, did not achieve statistical significance 
because of the overall low numbers of such antibodies.
Discussion
Overall, during the solid-phase screening period, a 
small but statistically significant increase in the number of 
antibodies detected relative to number of screens performed 
was identified (1.81% vs. 1.56%). Solid-phase screening was 
associated with a statistically significant decrease in the 
number of detected K antibodies. Although the numbers of 
other clinically significant antibodies such as anti-Jka, anti-
Jkb, and anti-Fyb were increased with solid-phase testing 
as compared with gel screening, the small numbers overall 
led to a lack of a statistically significant change. Continued 
surveillance for such changes will be necessary to determine 
whether the change in frequency reaches clinical significance 
as the number of samples tested increases.
These differences may be attributable to the sensitivity 
and specificity of the assays or other clinical variables such as 
transfusion practices and patient populations, which may have 
changed during the study period. Such clinical differences 
may lead to significant changes in transfusions per patient 
and the subsequent number of antibodies formed. Differences 
in patient population or medical practice can be studied in a 
retrospective manner as has been done previously.1,5,9 These 
variables cannot be fully evaluated with the current data. A 
subsequent study is planned to more fully answer this question 
by looking at length of stay in the hospital as well as overall 
RBC transfusions during those periods. A study performing 
simultaneous screens with both methods would allow for 
some of these questions to be answered, but it is impractical 
at this time as the gel method is no longer performed at our 
institution.
Others have looked simultaneously at gel and solid-phase 
methods but have had varying results as to which method is 
more sensitive.9 In a comparison of multiple methods including 
three gel and two solid-phase methods, Weisbach et al.10 
showed that one solid-phase method appeared superior to the 
gel methods in terms of specificity of antibody identification, 
although the other was inferior when tested on stored samples. 
In the study by Garozzo et al.,11 testing of clinical samples was 
performed simultaneously, as part of routine practice, using 
both solid-phase and gel methods, yielding similar results for 
screening and identification. Finally, in the most recent study 
of Haywood et al.,12 tube methods outperformed both solid-
phase and gel methods on referral specimens for antibody 
identification at an immunohematology reference center. 
Our study extends these results. Importantly, all testing was 
performed as part of routine practice on fresh samples from a 
single institution, making it an accurate reflection of standard 
conditions for antibody screening. In addition, all data were 
analyzed in a statistically rigorous manner to determine 
whether significant differences in the overall methods and for 
specific antibody identification existed, which had not been 
done previously.
Inevitably, different methods will yield different 
sensitivities and specificities of antibody detection. In 
combination with other considerations such as cost, workflow, 
and time, laboratories must choose which methods are optimal 
for their patient populations and operations. Extended side-
by-side comparisons of different methods would be optimal, 
but this is not always possible or practical. Alternatively, and 
perhaps regardless of such prospective comparison testing, 
it is advisable that laboratories continue to monitor antibody 
detection rates after new methods have been adopted. If 
changes are noted as occurred in our laboratory, further 
analysis of clinical parameters such as the incidence of delayed 
hemolytic or serologic transfusion reactions, transfusion 
practice, and hospital lengths of stay may make it possible to 
determine the clinical significance of such changes.
Shortly, we will be transitioning our antibody screening 
to the next-generation platform for solid-phase technology. We 
will continue to monitor the rates of antibodies identified and 
analyze them to determine whether statistically significant 
changes occur.
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